CD8A and neoplasm: Interestingly, a more than 80 fold higher absolute number of tumor-specific CD8+ cells in the infusion product was observed among the 2 responding patients compared to the 4 non-responders (5418 x 106 vs. 67 x 106 CD8+ T cells (mean values)) (Table 2).